Shareholders Approve Significant Increase in Employee Stock Purchase Plan Shares
PAVM sits 21% above its 52-week low of $3.85 on light trading volume (0.2× avg).
Summary
PAVmed shareholders approved a significant increase in shares allocated to the Employee Stock Purchase Plan, alongside routine director re-elections and auditor ratification.
Key Events · Corporate Governance and Compliance · PAVM
-
ESPP Share Increase Approved
Stockholders approved amendments to the Employee Stock Purchase Plan (ESPP), increasing the total shares available by 200,000 (from 15,774 to 215,774 shares) and raising the annual evergreen provision limit from 5,556 to 500,000 shares. This introduces significant potential for future equity dilution.
-
Directors Re-elected
Ronald M. Sparks and Timothy Baxter were re-elected as Class A directors to the company's board, a routine governance matter.
-
Auditor Ratified
The appointment of CBIZ CPAs P.C. as the independent registered certified public accounting firm for 2026 was ratified by shareholders.
Analysis · PAVM · Industrial Applications And Services
Shareholders approved a substantial increase in the shares available under the Employee Stock Purchase Plan (ESPP), adding 200,000 shares and raising the annual evergreen limit to 500,000 shares. This represents a notable potential for future dilution, especially for a company that has recently issued a going concern warning and has a history of dilutive financing.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1528 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PAVM was trading at $4.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $33.4M. The 52-week trading range was $3.85 to $28.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.